Skip to content
Screener

Rigel Pharmaceuticals RIGL Accrued research and development

Accrued research and development at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$98M+60.7%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$6.81M+56.1%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$448K-59.0%
Alumis Inc. logo
Alumis Inc.ALMS
$35.96M+3.6%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$86K
BioSig Technologies, Inc. logo
BioSig Technologies, Inc.STEX
$167K

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$778.2M+29.7%
Enterprise value$822.1M+50.0%
P/E2.1×-4.0×
P/S2.6×+0.4×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept rigl:AccruedResearchAndDevelopmentLiabilityCurrent.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Line itemAs of / March 31, 2026As of / December 31, 2025 ⁽¹⁾
Current liabilities:
Accounts payable$4,486$7,191
Accrued compensation6,00911,914
Accrued research and development5,7425,524
Acquisition-related liabilities5,0005,000
Revenue reserves and refund liability28,08027,716
Loans payable, net, current portion29,86529,812
Other accrued liabilities9,67411,466

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's accrued research and development?
Rigel Pharmaceuticals (RIGL) reported accrued research and development of $5.74M in Q1 2026.
How has Rigel Pharmaceuticals's accrued research and development changed year-over-year?
Rigel Pharmaceuticals's accrued research and development increased by 23.5% year-over-year, from $4.65M to $5.74M.
What is the long-term trend for Rigel Pharmaceuticals's accrued research and development?
Over 5 years (2020 to 2025), Rigel Pharmaceuticals's accrued research and development has grown at a 2.5% compound annual growth rate (CAGR), from $4.89M to $5.52M.
What does accrued research and development mean?
This represents the estimated financial obligations incurred for ongoing research and development activities that have not yet been invoiced or paid. It reflects the company's commitment to external service providers, such as clinical research organizations, for work performed but not yet settled. Monitoring this helps assess the near-term cash requirements for the company's R&D pipeline.

Ask your AI about Rigel Pharmaceuticals's accrued research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude